Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
News and updates for Precision BioSciences, Inc. (Nasdaq: DTIL) center on its progress as a clinical stage gene editing company using the ARCUS platform to develop in vivo therapies for serious genetic and infectious diseases. Company announcements frequently highlight developments in its pipeline, clinical trial milestones, scientific publications, and capital markets activity.
A major focus of Precision’s news flow is PBGENE-HBV, the company’s wholly owned in vivo gene editing program for chronic hepatitis B. Updates include data from the global ELIMINATE-B trial, covering safety, dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), and biopsy evidence of ARCUS-mediated viral DNA editing. Press releases also describe regulatory designations such as Breakthrough Therapy status and the expansion of clinical trial sites across multiple countries.
Another recurring theme is PBGENE-DMD, a muscle-targeted excision program for Duchenne muscular dystrophy. News items discuss preclinical data on dystrophin restoration and functional muscle improvement, preparations for investigational new drug (IND) submissions, and plans for Phase 1/2 clinical studies in DMD patients with mutations in exons 45–55 of the dystrophin gene.
Investors can also find updates on partnered in vivo programs, such as ECUR-506 for neonatal onset OTC deficiency developed by iECURE using a licensed ARCUS nuclease, along with regulatory milestones like RMAT designation. Additional coverage includes progress in non-core ex vivo programs such as azer-cel, an allogeneic CAR T therapy being advanced by partners for lymphoma and autoimmune diseases.
Financial and corporate news, including quarterly results, equity offerings, and strategic priorities, round out the DTIL news stream. For those tracking gene editing, hepatitis B, DMD, and ARCUS-based therapies, this page provides an organized view of Precision BioSciences’ latest disclosures and clinical developments over time.
Precision BioSciences (NASDAQ: DTIL) announced the presentation of preclinical data on its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference in Cabo San Lucas, Mexico, from December 5-9, 2021.
The oral presentation, titled "Targeting Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo", is scheduled for December 6, 2021, at 11:25 AM ET. Preclinical research demonstrated that ARCUS technology reduced HBV s-antigen levels by 77% in infected human hepatocytes and achieved a durable 96% reduction in mouse models.
Precision BioSciences announced key leadership changes with Michael Amoroso appointed as President and CEO. The company is focusing on advancing its ARCUS gene editing platform, targeting three investigational new drug applications within three years. Financial results showed a revenue increase to $24 million for Q3 2021, up from $7.4 million in Q3 2020, primarily due to an agreement with iECURE. Despite increased R&D expenses at $25.9 million, the net loss narrowed to $11.3 million from $26 million year-over-year, showcasing operational progress.
Precision BioSciences (NASDAQ: DTIL) announced the acceptance of its abstract titled “Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine” for presentation at the SITC 36th Annual Meeting from November 10-14, 2021, in Washington, D.C. The study highlights a preclinical advancement using ARCUS gene editing to develop fludarabine-resistant CAR T cells, with a notable 70% reduction in dCK mRNA and improved tumor clearance in mice. The findings may enhance the potential of CAR T therapies in treating cancers resistant to conventional treatments.
Precision BioSciences (NASDAQ: DTIL) announced the addition of two experienced directors, Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D., to its Board. These appointments enhance the board's expertise in gene therapy and operational leadership. Dr. Wadsworth has nearly 30 years of experience in gene therapy development, while Ms. Piré brings extensive legal and business transformation skills. The company aims to advance three INDs/CTAs in the next three years, marking a significant phase in its growth strategy.
Precision BioSciences (NASDAQ: DTIL) has announced encouraging results from its Phase 1/2a study of PBCAR0191, targeting relapsed/refractory non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL). Enhanced lymphodepletion strategy improved the overall response rate (83%) and complete response rate (CR) among heavily pretreated subjects. Data will be presented at the ASH Annual Meeting on December 11-14, 2021. Notably, 80% of B-ALL patients responded positively, indicating potential for bridging to stem cell transplant.
Precision BioSciences, Inc. (DTIL) announced it will publish its financial results for Q3 2021 on November 10, 2021, and provide a business update. CEO Michael Amoroso will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021. The company utilizes its ARCUS® genome editing platform for developing CAR T and in vivo gene editing therapies targeting genetic and infectious diseases. Investors can access a live webcast of the chat on the company’s website.
Precision BioSciences, Inc. (NASDAQ: DTIL) announced that Dr. Derek Jantz, Chief Scientific Officer and Co-Founder, will present at the Jefferies Virtual Gene Therapy/Gene Editing Summit on
Precision BioSciences, a clinical-stage biotech company (NASDAQ: DTIL), announced an inducement grant for Michael Amoroso, its new President and CEO. The grant includes options to purchase 850,000 shares and restricted stock units valued at $237,000. The stock option has a 10-year term, with 25% vesting on October 15, 2022, and the remainder vesting quarterly over three years. Both awards comply with the company's 2021 Employment Inducement Incentive Award Plan, approved by the Compensation Committee.
Precision BioSciences (NASDAQ: DTIL) announced Michael Amoroso as the new President and CEO, effective October 15, 2021, succeeding Co-Founder Matt Kane. Amoroso brings extensive experience in operational management and commercial roles within gene and cell therapies, particularly in oncology. His leadership is expected to enhance the company's ARCUS genome editing platform and advance late-stage clinical strategies. The Board of Directors commended Kane's significant contributions to the company.
Precision BioSciences (DTIL), a clinical-stage biotechnology company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The pre-recorded presentation will be available for on-demand viewing on September 13, 2021, at 7:00 a.m. ET on the company’s website. Precision BioSciences focuses on developing allogeneic CAR T and in vivo gene correction therapies using its proprietary ARCUS® genome editing platform, targeting genetic and infectious diseases with its innovative pipeline.
FAQ
What is the current stock price of Precision Biosciences (DTIL)?
What is the market cap of Precision Biosciences (DTIL)?
